Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study - 12/05/18
, Morten Schmidt, PhD b, c, Dora K. Farkas, MSc b, Henrik T. Sørensen, DMSc b, Lars Iversen, DMSc aAbstract |
Background |
Mycosis fungoides (MF) and parapsoriasis are characterized by malignant proliferation and chronic inflammation, which may affect the risk for venous thromboembolism (VTE).
Objectives |
To examine the risk for VTE in patients with MF and parapsoriasis.
Methods |
We conducted a nationwide population-based cohort study in Denmark to examine the relative risk (RR) of VTE in 525 patients with MF and 634 patients with parapsoriasis compared with that in sex- and age-matched controls from the general population.
Results |
In patients with MF, the 10-year absolute risk for VTE was 3.4% (95% confidence interval [CI], 2.0-5.4). The adjusted RRs were 2.41 (95% CI, 1.49-3.90) for VTE and 4.01 (95% CI, 2.16-7.46) for pulmonary embolism. Notably, within the first 5 years after diagnosis with MF, the RR of pulmonary embolism was increased 6.7-fold (to 6.71 [95% CI, 2.86-15.72]). Patients with parapsoriasis had a 2.7-fold increased RR of VTE (to 2.67 [95% CI, 1.32-5.40]) in the absence of other established VTE risk factors.
Limitations |
We had no information regarding disease stage of MF and prescribed drugs.
Conclusion |
Patients with MF and parapsoriasis had an increased RR of VTE, although the absolute risk remained low. These findings should increase awareness of comorbidities in patients with MF and parapsoriasis.
Le texte complet de cet article est disponible en PDF.Key words : comorbidity, cutaneous T-cell lymphoma, deep venous thrombosis, mycosis fungoides, parapsoriasis, pulmonary embolism, venous thromboembolism
Abbreviations used : CI, DCR, DNRP, DVT, MF, PE, RR, VTE
Plan
| Funding sources: Supported by grants from LINAK A/S, Nordborg, and from the Program for Clinical Research Infrastructure (PROCRIN), established by the Lundbeck Foundation and the Novo Nordisk Foundation. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
Vol 78 - N° 6
P. 1077 - juin 2018 Retour au numéro
Article précédent
- Progression of undiagnosed cutaneous lymphoma after anti–tumor necrosis factor-alpha therapy
- Maria Estela Martinez-Escala, Alba L. Posligua, Heather Wickless, Audrey Rutherford, Kimberly A. Sable, Belen Rubio-Gonzalez, Xiaolong A. Zhou, Jason B. Kaplan, Barbara Pro, Jaehyuk Choi, Christiane Querfeld, Steven T. Rosen, Joan Guitart
- Pemphigus and hematologic malignancies: A population-based study of 11,859 patients
- Khalaf Kridin, Shira Zelber-Sagi, Doron Comaneshter, Erez Batat, Arnon D. Cohen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?